DNA2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL4334739	1.00	1/20
SCHEMBL1277854	0.83	1/20
SCHEMBL6537720	0.78	1/20
SCHEMBL19220845	0.72	1/20
SCHEMBL19220852	0.71	1/20
SCHEMBL6538006	0.68	1/20
SCHEMBL4739348	0.67	1/20
SCHEMBL3249310	0.67	1/20
SCHEMBL8790508	0.67	1/20
SCHEMBL3066032	0.66	1/20
SCHEMBL18589537	0.66	1/20
SCHEMBL6538035	0.63	1/20
SCHEMBL6538267	0.63	1/20
SCHEMBL6538378	0.63	1/20
SCHEMBL571879	0.63	1/20
SCHEMBL1244916	0.62	1/20
SCHEMBL19220847	0.62	1/20
SCHEMBL20153429	0.62	1/20
SCHEMBL6215533	0.61	1/20
SCHEMBL2976084	0.61	1/20

Clinical trials — most relevant to DNA2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Intracameral Antibiotic Safety Study	PHASE3	SUSPENDED
Lipiodol-TACE With Idarubicin for Hepatocellular Carcinoma	PHASE2/PHASE3	UNKNOWN
Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer	PHASE2	RECRUITING
Iloprost in Preventing Lung Cancer in Patients at High Risk for This Disease	PHASE2	COMPLETED
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies	PHASE1/PHASE2	RECRUITING
Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma	PHASE1/PHASE2	RECRUITING
Clinical and Pharmacological Study With 2B3-101 in Patients With Breast Cancer and Leptomeningeal Metastases	PHASE2	UNKNOWN
Chlorambucil in Metastatic PDAC Patients Bearing a Germ Line DNA Defects Repair Mutations (SALE Trial)	PHASE2	UNKNOWN
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma	PHASE1/PHASE2	COMPLETED
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer	PHASE2	ACTIVE_NOT_RECRUITING
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas	PHASE1	COMPLETED
Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas	PHASE1	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors	PHASE1	COMPLETED
AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers	PHASE1	COMPLETED
Spironolactone and XPB-1 Integrity in the TFIIH Complex	nan	ENROLLING_BY_INVITATION
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics	nan	UNKNOWN
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients	nan	COMPLETED
Plant Extracted Natural Compounds Impact on Stage IV Breast Cancer Survival Time and Remission.	nan	UNKNOWN
Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer	nan	UNKNOWN
A Pilot Study of Parenteral Testosterone and Oral Etoposide as Therapy for Men With Castration Resistant Prostate Cancer	nan	COMPLETED
Cooperative Huntington's Observational Research Trial	nan	UNKNOWN
Vascular Senescence and Atherosclerotic Plaque Vulnerability	nan	RECRUITING
Study of the Effect of Innate on the Inflammatory Response to Endotoxin	nan	RECRUITING
Study of Markers of Cosmic Radiation Exposure and Effect Among Flight Crews	nan	COMPLETED
Role of ADA SNPs in Subjects With Relapsing Multiple Sclerosis (RMS)	nan	UNKNOWN
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients	nan	ACTIVE_NOT_RECRUITING
DNA Damage & Repair Proteins In Patients With Atherosclerotic Coronary Artery Disease	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a DNA2 binder may also engage these)

Protein	Name	Similarity
E1BMP7	—	1.000	E1BMP7 →
Q6ZQJ5	—	1.000	Q6ZQJ5 →
Q5ZKG3	—	0.999	Q5ZKG3 →
Q8QHA5	—	0.998	Q8QHA5 →
D3ZG52	—	0.993	D3ZG52 →
NAT10	RNA cytidine acetyltransferase	0.982	landscape →
Q5RF63	—	0.982	Q5RF63 →
A2RUV5	—	0.982	A2RUV5 →
Q6AYJ1	—	0.981	Q6AYJ1 →
Q9UJA3	—	0.981	Q9UJA3 →
F6QXW0	—	0.981	F6QXW0 →
RECQL	ATP-dependent DNA helicase Q1	0.980	landscape →
POLQ	DNA polymerase theta	0.980	landscape →
Q6PCN7	—	0.979	Q6PCN7 →
PRMT9	Protein arginine N-methyltransferase 9	0.979	landscape →
Q6NTR1	—	0.979	Q6NTR1 →
Q2VPA6	—	0.979	Q2VPA6 →
Q8BTI9	—	0.979	Q8BTI9 →
Q10HL3	—	0.978	Q10HL3 →
Q9LQQ2	—	0.978	Q9LQQ2 →
P13705	—	0.978	P13705 →
Q99MV5	—	0.978	Q99MV5 →
Q8N1G2	—	0.978	Q8N1G2 →
Q95216	—	0.978	Q95216 →
Q9CWR2	—	0.978	Q9CWR2 →
Q6PCI6	—	0.978	Q6PCI6 →
Q5ZIB9	—	0.977	Q5ZIB9 →
Q9DBC3	—	0.977	Q9DBC3 →
P98192	—	0.977	P98192 →
Q14527	—	0.977	Q14527 →